Quoin Pharmaceuticals (NASDAQ:QNRX) & CERo Therapeutics (NASDAQ:CERO) Critical Review

CERo Therapeutics (NASDAQ:CERO) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Earnings and Valuation

This table compares CERo Therapeutics and Quoin Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30 million	($71.01)	0.00
Quoin Pharmaceuticals	N/A	N/A	-$15.81 million	($29.56)	-0.16

Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

CERo Therapeutics has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500.

Profitability

This table compares CERo Therapeutics and Quoin Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for CERo Therapeutics and Quoin Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1	2	0	0	1.67
Quoin Pharmaceuticals	1	0	1	0	2.00

CERo Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 263,057.89%. Given CERo Therapeutics’ higher probable upside, analysts clearly believe CERo Therapeutics is more favorable than Quoin Pharmaceuticals.

Institutional & Insider Ownership

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 0.4% of CERo Therapeutics shares are held by insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

CERo Therapeutics beats Quoin Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.